Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

R-BIOPHARM

R-Biopharm AG is a biotechnology company that offers innovative products for numerous applications in the area of cli... read more Featured Products: More products

Download Mobile App




Rapid Commercial Test for Campylobacter Evaluated

By LabMedica International staff writers
Posted on 13 Feb 2014
The effectiveness of a new rapid immunochromatographic test for the qualitative detection of Campylobacter antigens in pathologic feces has been evaluated. More...


The genus Campylobacter belongs to the family Campylobacteriaceae and contains 18 species, including Campylobacter jejuni, the cause of around 90% of acute Campylobacter enteritis cases in humans, a zoonotic disease prevalent worldwide and transmitted via water and food.

Microbiologists at the Hospital Universitario Virgen de las Nieves (Granada, Spain) examined 300 consecutive samples of fresh feces samples from patients diagnosed with diarrhea in primary (57.6%) and specialist (42.4%) care; 50.6% were from adults and 49.4% from children under 14 years of age, between March and May 2013. They were processed for coproculture immediately on their reception by culture and colonies suspected of being enteropathogenic were identified by means of the Biotyper system (Bruker Daltonics; Billerica, MA, USA).

The RIDAQUICK Campylobacter immunochromatographic test (R-biopharm AG; Darmstadt, Germany) was evaluated and compared with culture results. Campylobacter was considered present when the microorganism was isolated or when the specific DNA was detected in samples with contradictory culture and immunochromatographic findings. The results of the RIDAQUICK Campylobacter test was considered positive when violet red lines could be seen in the control (C) and test (T) bands, negative when the control line alone appeared, and invalid when no line could be observed.

Campylobacter was detected in 37 (12.3%) of all samples, and the gold-standard culture method was positive for C. jejuni in 31 (83.78%) of these. A different enteropathogen was detected in 12 (8.11%) of the samples from children. The culture and immunochromatographic results differed in 12 samples (4% of the total), which were therefore studied by polymerase chain reaction (PCR); six of these samples were culture-negative and PCR-positive and one was culture positive (C. jejuni) and PCR-negative.

The diagnostic accuracy values of the RIDAQUICK Campylobacter assay versus culture were: sensitivity of 87%, specificity of 97%, and positive and negative predictive values of 77% and 98%, respectively. RIDAQUICK Campylobacter was found to be a rapid test for the diagnosis of enteritis due to Campylobacter and could be an option for the clinical diagnosis of one of the main causes of bacterial enteritis in resource-limited settings. The study was published in the February 2014 issue of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Hospital Universitario Virgen de las Nieves
Bruker Daltonics
R-biopharm AG



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.